Business Wire

CA-VELODYNE-LIDAR,-INC.

7.1.2020 21:02:10 CET | Business Wire | Press release

Share
Velodyne Lidar Introduces Velabit™

Velodyne Lidar, Inc. today introduced Velabit™, Velodyne’s smallest sensor which brings new levels of versatility and affordability to 3D lidar perception, at CES 2020. The Velabit leverages Velodyne’s innovative lidar technology and manufacturing partnerships for cost optimization and high-volume production. The sensor advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005849/en/

The Velabit perfectly complements Velodyne’s sensor portfolio. The sensor delivers the same technology and performance found on Velodyne’s full suite of state-of-the-art sensors and will be the catalyst for creating endless possibilities for new applications in a variety of industries. The compact Velabit can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs), infrastructure and more. It is designed to be easy to manufacture at mass production levels.

The Velabit is engineered to be an optimal automotive grade lidar solution for Advanced Driver Assistance Systems (ADAS) and autonomous vehicles. It enables robust perception coverage for Blind-Spot Monitoring, Cross Traffic Detection, Automatic Emergency Braking, and Pedestrian and Bicyclist Safety. Highly configurable for customer application, this mid-range sensor can be combined with other Velodyne lidar sensors, such as the Velarray™, for high-speed operation or function as a standalone lidar solution in low-speed applications.

The Velabit addresses the cost, safety and design challenges of autonomous solutions while delivering strong sensor performance. Here are the Velabit’s leading features:

  • Integrated processing in a compact size of 2.4” x 2.4” x 1.38” – smaller than a deck of playing cards – to be easily embedded in a wide range of solutions.
  • Range up to 100 meters.
  • Outstanding field of view (FoV): 60-degree horizontal FoV x 10-degree vertical FoV.
  • Highly configurable to support a range of applications.
  • Proven, Class 1 eye-safe 903 nanometer technology.
  • Bottom connector with cable length options.
  • Multiple manufacturing sources scheduled to be available for qualified production projects.

“The Velabit democratizes lidar with its ultra-small form factor and its sensor pricing targeted at $100 in high-volume production, making 3D lidar available for all safety-critical applications,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Its combination of performance, size and price position the Velabit to drive a quantum leap in the number of lidar-powered applications. The sensor delivers what the industry has been seeking: a breakthrough innovation that can jump-start a new era of autonomous solutions on a global scale.”

“Before the Velabit there was no suitable small and lightweight lidar for small unmanned aerial vehicles and unmanned ground vehicles performing obstacle avoidance or mapping,” said Alberto Lacaze, president, Robotic Research. “Since Robotic Research’s Pegasus Mini™ is a fully autonomous ground and air vehicle, it requires the Velabit’s size and versatility. In addition, the Velabit enables the most advanced GPS-denied HD mapping in the industry. The Velabit fills a much-needed space in the market and is currently in a class of its own.”

The Velabit will be available to customers mid-2020. Velodyne provides world-class technical support for the sensor across North America, Europe and Asia. It is now on display at Velodyne Lidar’s CES 2020 booth located at the Las Vegas Convention Center North Hall – booth #7520.

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.

Contact:

Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com

Link:

ClickThru

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye